Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the Phase IIb RELIEVE UCCD trial of duvakitug.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Sanofi and Teva Pharmaceuticals ... in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).

TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn ...